Cargando…
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refractory (R/...
Autores principales: | Zou, Yixin, Xu, Wei, Li, Jianyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247712/ https://www.ncbi.nlm.nih.gov/pubmed/30458878 http://dx.doi.org/10.1186/s13045-018-0676-3 |
Ejemplares similares
-
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016) -
Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019) -
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
por: Zhang, Erhao, et al.
Publicado: (2018) -
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018) -
Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2020)